Abteilung für Klinische Pharmakologie
  1. Startseite LMU Klinikum
  2. Abteilung für Klinische Pharmakologie
  3. Prof. Dr. med. Sebastian Kobold

Prof. Dr. med. Sebastian Kobold

Abt. Klinische Pharmakologie Medizinische Klinik und Poliklinik IV

Principal Investigator

+49 (0)89 4400-57325
+49 (0)89 4400-5 7330
Lindwurmstraße 2a
München, 80337

Curriculum vitae

  • Since 2019   Professor of Medicine and Experimental Immunooncology (W2-level), Deputy Director, Faculty of Medicine, Division of Clinical Pharmacology, University Hospital of Ludwig-Maximilian University Munich (KUM), Germany.
  • Since 2016   Attending Physician, Division of Clinical Pharmacology, KUM, Germany.
  • 2014     Habilitation in Experimental Internal Medicine, Faculty of Medicine, Ludwig-Maximilians-University Munich (LMU), Germany, Topic: antibody therapy. Supervisors: S. Endres, W. Zimmermann and R. Henschler.
  • 2014     Board Certification as Clinical Pharmacologist and Immunologist. Bavarian Chamber of Physicians and German Society of Immunology (DGFI).
  • 2010     Dr. med. (medical doctorate), Faculty of Medicine, Saarland University, Homburg, Germany; Supervisors: Renner C., Knuth, Title: “Serologische Identifikation von Pankreaskarzinom-spezifischen Antigenen".
  • 2007     Graduation from Medical School and German Licence to practice Medicine. Faculty of Medicine, Saarland University, Homburg, Germany, with electives in Bordeaux, France, Zürich, Switzerland and Homburg, Germany.

  • 2023 Georges-Köhler Award, German Society for Immunotherapy, Germany.
  • 2022 Monika-Kutzner Award for Cancer Research, Berlin-Brandenburg Academy of Sciences, Germany.
  • 2021 Lisec-Artz Award for Cancer Research, Medicine Faculty – University of Bonn, Germany.
  • 2020 Clinical Science Award, German Society for Immunotherapy, Germany.
  • 2019 M4-preseed Award by the Bavarian Ministry of Economical Affairs.
  • 2019 Johann-Georg-Zimmermann Award for Cancer Research, University of Hannover, Germany.
  • 2017 European Research Council (ERC) Starting Grant, Brussels, Belgium.
  • 2017 Hugo-Wilhelm- von Ziemsen Award for medical research, Department of Internal Medicine IV, University Hospital of Ludwig-Maximilian University Munich (KUM), Germany.
  • 2016 Vincenz-Czerny Award for Cancer Research, German Society of Hematology and Oncology, Germany.
  • 2016 BMS-MRA Young Investigator Award, awarded by the Melanoma Research Alliance, Washington D.C., USA.
  • 2016 Career Advancement Award 2016 of the Jung-Foundation for Science and Research, Hamburg, Germany.
  • 2016 Young investigator Award, Melanoma Research Alliance, Washington D.C., USA.

  • 2023     Section Editor at the Journal for the Immunotherapy of Cancer (JIF 12.5), official journal of the Society for the Immunotherapy of Cancer (SITC).
  • 2022     Editorial Board Member, ESMO IOTECH.
  • 2020     Associate Editor for the Section Cancer Immunity and Immunotherapy. Frontiers in Immunology (JIF 5) and Frontiers in Oncology (JIF 4.8).

  • Bispecific antibody molecules with antigen-transfected T cells and their use in medicine. Kobold S, Bourquin C, Castoldi R, Sustmann C, Niederfellner G, Klein C and Endres S. PCT/EP2013/051351.
  • PD1-CD28 fusions proteins and their use in medicine. Kobold S and Endres S. PCT/EP2016/064195.
  • CXCR6 transduced T cells for targeted tumor therapy. Kobold S, Grassmann S, Rapp M and Endres S. EP15190179.0, submitted on October 16th 2015.
  • Improving adoptive cellular therapy. Kobold S, Geiger M, Sustmann C, Niederfellner G, Klein C and Endres S. EP16177203, submitted on June 30th 2016.
  • CCR8 transduced T cells for targeted tumor therapy. Kobold S, Cadilha BL and Endres S. EP19161708.3, submitted on march 3rd 2019.
  • CSF1R-targeted immunotherapies. Kobold S, Lesch S, Gottschlich A, Endres S. EP21191376, submitted on August 13th 2021.